analyst
ER
NASDAQ · ERAS
Erasca, Inc.
Healthcare · Biotechnology
$15.36
Down-$0.89 (-5.48%)
Updated Sep 17, 2026, 10:01 AM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 958.95M
- P/E ratio
- -7.47
- Dividend yield
- 0.00%
- 52-week range
- $1.59 – $24.28
- Volume
- 6.09M
- Avg. volume
- 1.84M
Price performance
ERAS price history
1M range · 20 trading sessions · Daily adjusted prices
ERAS closed at $15.36 after 20 trading sessions, down 15.00% for the selected period.
- Last close
- $15.36
- Period change
- -15.00%
- Period low
- $15.36
- Period high
- $19.49
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $16.31 | $16.64 | $15.19 | $15.36 | 6.09M |
| Sep 15, 2026 | $16.135 | $16.29 | $15.535 | $16.25 | 4.69M |
| Sep 14, 2026 | $16.06 | $16.53 | $15.97 | $16.16 | 2.37M |
| Sep 11, 2026 | $16.05 | $16.54 | $15.87 | $15.88 | 2.88M |
| Sep 10, 2026 | $15.37 | $17.25 | $15.37 | $16.03 | 8.25M |
| Sep 9, 2026 | $16.06 | $16.70 | $15.67 | $15.70 | 4.04M |
| Sep 8, 2026 | $15.88 | $16.65 | $15.68 | $16.28 | 4.26M |
| Sep 4, 2026 | $16.04 | $16.40 | $15.77 | $16.19 | 2.06M |
| Sep 3, 2026 | $16.38 | $16.57 | $16.09 | $16.26 | 3.76M |
| Sep 2, 2026 | $16.97 | $17.45 | $15.78 | $16.37 | 5.12M |
| Sep 1, 2026 | $17.58 | $17.95 | $16.68 | $16.76 | 6.71M |
| Aug 31, 2026 | $17.87 | $18.03 | $17.14 | $17.88 | 4.77M |
| Aug 28, 2026 | $19.25 | $19.59 | $18.00 | $18.03 | 2.89M |
| Aug 27, 2026 | $19.30 | $20.40 | $19.14 | $19.49 | 4.12M |
| Aug 26, 2026 | $17.57 | $19.50 | $17.24 | $19.15 | 7.69M |
| Aug 25, 2026 | $17.80 | $18.50 | $17.70 | $17.76 | 2.66M |
| Aug 24, 2026 | $18.41 | $18.66 | $16.88 | $17.60 | 2.24M |
| Aug 21, 2026 | $17.28 | $17.835 | $17.21 | $17.63 | 2.45M |
| Aug 20, 2026 | $17.59 | $17.77 | $16.92 | $17.08 | 2.67M |
| Aug 19, 2026 | $18.77 | $18.77 | $17.705 | $18.07 | 3.31M |
Latest ERAS news
The latest Smart Investors Daily articles mentioning ERAS.
Stock researchResearch & News · SEC Filings
Loading stock research…